Avricore Health Inc.

As of June 30, 2026, Avricore Health Inc. carries a market capitalization of 6.95M, placing it among publicly traded companies globally. Its enterprise value stands at 6.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Avricore Health Inc. has 126.37M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 29.11, and the price-to-book ratio stands at 6.26.

These figures are as of June 30, 2026. The EV/Sales ratio of 31.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.03M versus a market cap of 6.95M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Avricore Health Inc. maintains a current ratio of 8.24, meaning it holds 8.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Avricore Health Inc. posted a negative return on equity (ROE) of -132.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -124.05, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Avricore Health Inc.'s stock has declined approximately 16.67% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.12.

Over the twelve months ended June 30, 2026, Avricore Health Inc. generated 193,041.00 in revenue and converted that into -1.80M in net income, yielding earnings per share of -0.02. EBITDA reached -1.72M, while operating income came in at -1.20M.

These figures are as of June 30, 2026. Total book value stands at 1.11M, with working capital of 934,882.00 providing operational flexibility.

Avricore Health Inc. produced -1.10M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -22,946.00 in capital expenditures, free cash flow totaled -1.13M - equivalent to -0.01 per share.

Over the twelve months ended June 30, 2026, Avricore Health Inc. posted a gross margin of -34.72, reflecting its pricing power and cost economics. The operating margin of -621.35 and net profit margin of -933.80 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -20.06: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

Avricore Health Inc.'s most recent stock split took place on November 21, 2016 with a 4:1 split ratio.

As of June 30, 2026, Avricore Health Inc. has an Altman Z-Score of -9.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.